ArticleJHEP reports : innovation in hepatology2025
Alcohol-related hepatitis induces a specific fibrosis profile through YAP activation in myofibroblasts.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Yes-associated protein (YAP) impairs hepatocyte regeneration in alcohol-related hepatitis (AH), but its impact on fibrogenesis remains to be characterized. Our aim here was to describe fibrogenesis and investigate the impact of altered hepatocytes on fibrogenic mechanisms during AH. Methods: Fibrosis, YAP and alpha smooth muscle actin (αSMA) distribution were assessed by immunostaining. Extracellular matrix (ECM) composition in severe AH (n = 22), alcohol-related cirrhosis without AH (Cirrh, n = 24), and healthy livers (CTRL, n = 15) was assessed by PCR, and bulk and spatial proteomics. The impact of organoids generated from AH and Cirrh livers on myofibroblasts was also evaluated. Cirrh organoids were transduced with constitutively active YAP (to mimic AH organoids) and co-cultured with myofibroblasts in a 3D co-culture model. In a 2D model, myofibroblasts were treated with growth differentiation factor 15 (GDF15) or cultured with medium from transduced (YAP medium) and non-transduced hepatocytes. Results: AH livers presented with both perilobular (as in Cirrh livers) and specifically intralobular fibrosis. Bulk proteomics and PCR showed a specific ECM protein signature ( Conclusion: AH displays a specific fibrosis profile and protein signature. AH organoids and YAP-transduced Cirrh organoids induce myofibroblast activation. Thus, hepatocyte YAP activation has an important role in the fibrogenesis observed in AH. Impact and implications: Aberrant activation of YAP in hepatocytes contributes to impaired regeneration in alcohol-related hepatitis (AH) by driving their transdifferentiation toward a cholangiocyte-like phenotype. Preliminary data suggest that the extracellular matrix in AH differs from cirrhosis, with an increased laminin-to-fibronectin ratio. In a 3D co-culture model of liver organoids and myofibroblasts, AH organoids increased activation and proliferation of myofibroblasts compared with cirrhosis organoids. Aberrant YAP activation in altered hepatocytes is involved in the activation and proliferation of myofibroblasts in AH livers. Thus, inhibiting YAP in hepatocytes could be an attractive approach for the development of AH treatments to improve hepatic regeneration and decrease fibrogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.